ANZCTR search results

This study will recruit participants who attend Armadale Hospital (public) Emergency Department (ED) with acute low back pain. They will be randomized into groups, and the intervention group fitted with an abdominal brace. The hypothesis is that in people with mechanical low back pain, wearing a brace will reduce their pain (and increase activity and quality of life [QoL]). The participants will be asked to wear the brace for up to 30 days when in pain during the day and if they feel that the brace is helpful. Low back pain, function, QoL and health care usage will be tracked for 3 months from the date of attendance at ED.

This is a randomised, blinded and controlled Phase I trial to measure the safety, feasibility and efficacy of a combined cell transplantation and intensive rehabilitation intervention to treat spinal cord injury. The trial aims to examine whether transplantation of olfactory cell nerve bridges combined with intensive rehabilitation is safe and feasible for people living with chronic spinal cord injury in Australia, and whether the intervention improves structural integrity of the spinal cord, functional recovery, overall health, and social well-being.

Study approved by bellberry ethics committee K on 19th February 2024. This is a single-centre, single ascending dose study to assess the safety of lanreotide Extended-Release Formulation, and how this drug acts in the body in healthy volunteers. Lanreotide may be indicated for use in patients with neuroendocrine cancer, but a trial of the drug in healthy volunteers is needed before trials in cancer patients can proceed. Who is it for? You may be eligible for this study if you are aged 18 to 55 years and are in good general health without a clinically significant medical history. People who have been diagnosed with cancer will not be eligible for this study. Participants who choose to enrol in this study may be enrolled into one of three dose cohorts. Healthy volunteer participants may receive either a single dose of lanreotide ERF administered as a subcutaneous (under the skin) injection or a single dose of lanreotide ERF administered as an intramuscular (into a muscle) injection. All participants will have their vital signs checked and will provide blood samples for testing. It is hoped this research will determine the maximum dose and best injection method for lanreotide ERF that can be administered safely without causing severe reactions. Once the dose of lanreotide ERF has been determined in healthy volunteers, a trial investigating the efficacy of lanreotide ERF as a treatment for neuroendocrine cancer patients may proceed.

Cardiovascular disease is the leading cause of death and disability among adults globally. In Australia it is the lead contributor to health care expenditure and with an ageing population the burden of disease is expected to increase. Cardiac rehab is an effective secondary prevention tool post acute coronary syndrome acute coronary syndrome but is underutilised and inconsistently delivered. The trial will whether early cardiac rehabilitation in high-risk acute coronary syndrome results in greater functional improvement at 6 months when compared to later and standard of care, examine the safety of cardiopulmonary testing to support exercise prescription, and define the metabolic profiles of post acute coronary syndrome.

This study is looking at follicular unit extraction to treat hidradenitis suppurativa, a condition that causes inflammation of hair follicles resulting in severe pain and scarring. Follicular unit extraction is a technique used in hair transplants to entirely remove hair follicles. We want to test whether or not by removing hair follicles using hair follicle extraction technique reduces inflammation and improve the quality of patients’ life. We will do hair follicle extraction on both sides of either the armpit or groin and compare it with topical routine treatments to assess whether or not there is improvement. We will follow the participants until week 24 of the study.

Post-stroke fatigue is a common and debilitating consequence of stroke, affecting over half of all stroke survivors, which can persist for years and interferes with recovery. Education is recommended but stroke survivors report that health professionals provide minimal information about fatigue that is difficult to apply to their daily life. This project will evaluate a co-designed education tool called the Fatigue-o-meter via a proof-of-concept study design.

Heart2Heart is a community-based randomised controlled trial with 12 months follow-up. The aim of the study is to determine whether implementation of a digital peer support program for people living with CHD is effective in improving social connectedness, clinical and patient-reported outcomes and experience measures. The intervention group will have access to a 6-month intervention that enables peer support via an interactive mobile application, which includes online discussion groups, access to resources and facilitated conversations with health professionals. If effective, the digital peer support intervention has the potential to increase social connectedness and empower people to self-manage and support others through sharing lived experience and learning.

Current pharmacotherapy options of haemodynamic support in critically ill patients with vasodilatory hypotension are limited. Centhaquine is a novel agent that has a dual action on the sympathetic system and may helped in the management of hypotensive states. We hypothesise that, compared to placebo, centhaquine will be associated with higher stroke volume, higher central venous pressure, higher mean arterial pressure, and lower vasopressor agent use over six hours after initiation of the study infusion. We plan to enrol 18 adult patients.

The Bridging Study aims to evaluate, implement and upscale the Navicare model of care. In the Navicare model of care, a Care Navigator links help seekers with supports they may need to improve their mental wellbeing. The Care Navigator assists with referrals, makes appointments with mental health care professionals, and provides a private space in which to access online mental health support from online psychology and other service providers. The Navicare model currently exists in the town of Moranbah (“Hub 1”), in the Bowen Basin region of Queensland. The Bridging Study will evaluate Navicare in three new sites. The study hypothesises that implementation of Navicare, using a locally tailored approach that addresses barriers to implementation supported by evidence-informed implementation strategies, will sustain access (primary outcome) to mental health services in regional settings in the post-implementation period compared to the implementation and pre-implementation period. It also hypothesises that sites that engage more with Navicare will be more successful in sustaining improved access and uptake of mental health services, and reducing crisis mental-health-related Emergency Department (ED) presentations, mental-health related time in Emergency Departments, and overnight hospitalisations compared to the implementation and pre-implementation periods; and will improve access and uptake of mental health services in the implementation period compared to the pre-implementation period.

This project seeks to undertake a prospective longitudinal natural history study to generate a comprehensive phenotypic profile of biological, behavioural, clinical, neurocognitive and neurophysiological markers associated with INDD and its progression; and correlate with the genotype when clinically available. This work will provide more complete neurobiological descriptions, novel mechanistic insights, and clear recommendations regarding candidate biomarkers for diagnosis and treatment tracking.